iRT-ABCDEFG |
Tips |
G |
Goals are less MACCE and diabetic complications, less
medical costs, longer life expectancy, lower morbidity and mortality,
and higher quality of life. |
F |
Follow-up with registered subjects or patients, especially
populations with family history, IGT, and an unhealthy lifestyle for
primary and secondary prevention, tracking outcome and evaluating
effects of intensive medical therapy (oral drugs or insulin injection)
and surgery. It’s very important for a population-based
study. |
E |
Examination for early diagnosis, treatment, and prevention,
which includes large-scale screening and regular comprehensive or
targeted physical examinations, such as biomarkers (fasting
blood-glucose, postprandial blood glucose, hemoglobin Alc, and others:
FGF21, lipoprotein(a), microalbuminuria, RAGE, salusin-α and salusin-β),
oral glucose tolerance test, ß cell function, genetic variants (e.g.
nitric oxide synthase 1 adaptor protein, FOXO1 gene), ultrasonography,
histopathological analysis, coronary angiography, CT angiography & MRI.
Risk stratification following these examinations and related scoring
will improve treatment and clinical outcomes. |
D |
Diseases and risk factor control, which includes
prediabetes state or impaired glucose tolerance, hypertension,
dyslipidemia, chronic infection, and diabetic complications (e.g.
retinopathy or chronic kidney disease, hypoglycemia, peripheral
neuropathy, diabetic ketoacidosis and other CVDs), obesity, physical
inactivity, and heavy drinking or smoking. |
C |
Change unhealthy E(e)SEEDi lifestyle with
SEEDi1.0-3.0 technologies, such as not staying up
late, being physically active, no smoking and drinking; Chinese
medicine is a good choice; Controlling the source of infection
and the spread of pathways during the pandemic are
vital strategies if accompanied by acute infectious diseases (e.g.
COVID-19); And Cutting off the genetic pathways by RNAi, gene
knockout or CRISP/Cas9 gene editing after an ethical approval and
patients consent due to a genetic predisposition to
diabetes. |
B |
Biohazard control, which includes abnormal symptoms and
physiological indexes, HbA1c level of bio-markers, family history,
intensive weight management for obesity, and control of diabetic
complications. Monitoring or self-monitoring of blood glucose levels is
important and necessary. |
A |
Antagonistic treatment, which includes oral hypoglycemic
agents (such as GLPR agonists, SGLT2 inhibitors), insulin monotherapy,
statin-based treatment, bariatric surgery, guidelines and other related
methods. |
iRT |
intervention with these strategies as Routine,
Right & Reversible Treatment. |